



## Clinical trial results:

### Multicentre, Single-Arm, Open-Label, Clinical Trial Intended to Provide Early Access to Cabazitaxel in Patients with Metastatic Hormone Refractory Prostate Cancer Previously Treated with a Docetaxel-Containing Regimen and to Document Safety of Cabazitaxel in These Patients

#### Summary

EudraCT number	2010-021128-92
Trial protocol	GB CZ BE DK ES IT SE FI AT PT HU IE BG SK
Global end of trial date	21 December 2014

#### Results information

Result version number	v1 (current)
This version publication date	24 July 2016
First version publication date	24 July 2016

#### Trial information

##### Trial identification

Sponsor protocol code	CABAZ_C_05331
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01254279
WHO universal trial number (UTN)	U1111-1115-2476

Notes:

#### Sponsors

Sponsor organisation name	Sanofi aventis recherche & développement
Sponsor organisation address	1 avenue Pierre Brossolette, Chilly-Mazarin, France, 91380
Public contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact- US@sanofi.com
Scientific contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact- US@sanofi.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 December 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 December 2014
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To allow subjects similar to those evaluated in the TROPIC trial (EFC1693) , and Investigators access to cabazitaxel for the management of metastatic Hormone Refractory Prostate Cancer (mHRPC) in subjects who had progressed during or after docetaxel, and to document the overall safety of cabazitaxel in these subjects.

Protection of trial subjects:

Subjects were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the subject and considering the local culture. During the course of the trial, subjects were provided with individual subject cards indicating the nature of the trial the subject is participating, contact details and any information needed in the event of a medical emergency. Collected personal data and human biological samples were processed in compliance with the Sanofi-Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 December 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 5
Country: Number of subjects enrolled	Portugal: 20
Country: Number of subjects enrolled	Romania: 16
Country: Number of subjects enrolled	Slovakia: 15
Country: Number of subjects enrolled	Spain: 156
Country: Number of subjects enrolled	Sweden: 8
Country: Number of subjects enrolled	United Kingdom: 112
Country: Number of subjects enrolled	Austria: 7
Country: Number of subjects enrolled	Belgium: 45
Country: Number of subjects enrolled	Bulgaria: 21
Country: Number of subjects enrolled	Czech Republic: 15
Country: Number of subjects enrolled	Denmark: 24
Country: Number of subjects enrolled	Finland: 13
Country: Number of subjects enrolled	Hungary: 18
Country: Number of subjects enrolled	Ireland: 22
Country: Number of subjects enrolled	Italy: 219

Country: Number of subjects enrolled	Luxembourg: 1
Country: Number of subjects enrolled	Australia: 104
Country: Number of subjects enrolled	Bosnia and Herzegovina: 13
Country: Number of subjects enrolled	Canada: 61
Country: Number of subjects enrolled	Croatia: 6
Country: Number of subjects enrolled	India: 6
Country: Number of subjects enrolled	Kazakhstan: 13
Country: Number of subjects enrolled	Malaysia: 5
Country: Number of subjects enrolled	Mexico: 12
Country: Number of subjects enrolled	Philippines: 6
Country: Number of subjects enrolled	Serbia: 10
Country: Number of subjects enrolled	Singapore: 5
Country: Number of subjects enrolled	Taiwan: 23
Worldwide total number of subjects	981
EEA total number of subjects	723

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	298
From 65 to 84 years	676
85 years and over	7

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study was conducted in 29 countries. A total of 981 subjects were enrolled between 20 December 2010 and 27 September 2013.

### Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Cabazitaxel
-----------	-------------

Arm description:

Cabazitaxel 25 mg/m<sup>2</sup> administered on Day 1 of each 3-weeks cycle in combination with prednisone or prednisolone 10 mg daily until disease progression, death, unacceptable toxicity or Investigator's decision.

Arm type	Experimental
Investigational medicinal product name	Cabazitaxel
Investigational medicinal product code	XRP6258
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Cabazitaxel 25 mg/m<sup>2</sup> intravenous (IV) infusion administered for one hour.

Investigational medicinal product name	Prednisone/Prednisolone
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Prednisone or prednisolone 10 mg daily administered according to its labelling.

Number of subjects in period 1	Cabazitaxel
Started	981
Disease Progression	457 <sup>[1]</sup>
Adverse Events	254 <sup>[2]</sup>
Physician/Investigator's Decision	159 <sup>[3]</sup>
Cabazitaxel Commercially Available	4 <sup>[4]</sup>
Other than specified	107 <sup>[5]</sup>
Completed	981

---

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Met EOT criteria (treatment until disease progression, death, unacceptable toxicity [AE], Investigator's decision or cabazitaxel commercially available).

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Met EOT criteria (treatment until disease progression, death, unacceptable toxicity [AE], Investigator's decision or cabazitaxel commercially available).

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Met EOT criteria (treatment until disease progression, death, unacceptable toxicity [AE], Investigator's decision or cabazitaxel commercially available).

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Met end of treatment (EOT) criteria (treatment until disease progression, death, unacceptable toxicity [AE], Investigator's decision or cabazitaxel commercially available).

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Met EOT criteria (treatment until disease progression, death, unacceptable toxicity [AE], Investigator's decision or cabazitaxel commercially available).

## Baseline characteristics

### Reporting groups

Reporting group title	Cabazitaxel
-----------------------	-------------

Reporting group description:

Cabazitaxel 25 mg/m<sup>2</sup> administered on Day 1 of each 3-weeks cycle in combination with prednisone or prednisolone 10 mg daily until disease progression, death, unacceptable toxicity or Investigator's decision.

Reporting group values	Cabazitaxel	Total	
Number of subjects	981	981	
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	68.2 ± 7.7	-	
Gender categorical Units: Subjects			
Female	0	0	
Male	981	981	

## End points

### End points reporting groups

Reporting group title	Cabazitaxel
Reporting group description: Cabazitaxel 25 mg/m <sup>2</sup> administered on Day 1 of each 3-weeks cycle in combination with prednisone or prednisolone 10 mg daily until disease progression, death, unacceptable toxicity or Investigator's decision.	

### Primary: Number of Subjects with Early Access to Cabazitaxel

End point title	Number of Subjects with Early Access to Cabazitaxel <sup>[1]</sup>
End point description: Safety population included the subjects who had signed the informed consent form and had received at least part of one dose of cabazitaxel.	
End point type	Primary
End point timeframe: From enrollment up to 30 days after the last administration of study drug (205 weeks + 30 days).	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.

End point values	Cabazitaxel			
Subject group type	Reporting group			
Number of subjects analysed	981			
Units: Subjects				
number (not applicable)	981			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects with Treatment-Emergent Adverse Events (TEAE)

End point title	Percentage of Subjects with Treatment-Emergent Adverse Events (TEAE)
End point description: An Adverse Event (AE) was defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which did not necessarily had a causal relationship with this treatment. AEs that occurred or worsened after the first day of dosing upto 30 days after the last administration of Cabazitaxel, were considered as treatment-emergent adverse events (TEAE). A serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included subjects with both serious and non-serious AEs. Analysis was performed on safety population.	
End point type	Secondary
End point timeframe: From enrollment upto 30 days after the last administration of study drug (205 weeks + 30 days)	

<b>End point values</b>	Cabazitaxel			
Subject group type	Reporting group			
Number of subjects analysed	981			
Units: Percentage of Subjects				
number (not applicable)				
Any TEAE	95.2			
Any possibly related TEAE	86.2			
Any serious TEAE	40.8			
Any TEAE leading to death	6.6			
Any TEAE leading to treatment discontinuation	25.8			

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (205 weeks + 30 days) regardless of seriousness or relationship to investigational product.

Adverse event reporting additional description:

Reported adverse events and death are treatment-emergent adverse events that is AEs that developed/worsened and death that occurred during the 'on treatment period' (the period from the first administration of study drug up to 30 days after the last administration of study drug).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.0
--------------------	------

### Reporting groups

Reporting group title	Cabazitaxel
-----------------------	-------------

Reporting group description:

Cabazitaxel 25 mg/m<sup>2</sup> administered on Day 1 of each 3-weeks cycle in combination with prednisone or prednisolone 10 mg daily until disease progression, death, unacceptable toxicity or Investigator's decision.

Serious adverse events	Cabazitaxel		
Total subjects affected by serious adverse events			
subjects affected / exposed	400 / 981 (40.77%)		
number of deaths (all causes)	216		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Bladder Cancer			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Brain Neoplasm Malignant			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metastases To Central Nervous System			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metastases To Lung			

subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metastases To Spine			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Metastatic Pain			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Circulatory Collapse			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Deep Vein Thrombosis			
subjects affected / exposed	6 / 981 (0.61%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 0		
Embolism Venous			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Haematoma			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypovolaemic Shock			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Lymphoedema			

subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	6 / 6		
deaths causally related to treatment / all	0 / 0		
Orthostatic Hypotension			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Venous Thrombosis			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 0		
Venous Thrombosis Limb			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Medical Device Change			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	6 / 981 (0.61%)		
occurrences causally related to treatment / all	5 / 7		
deaths causally related to treatment / all	0 / 0		
Chest Pain			
subjects affected / exposed	3 / 981 (0.31%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 0		
Death			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	2 / 2		

Device Occlusion				
subjects affected / exposed	5 / 981 (0.51%)			
occurrences causally related to treatment / all	0 / 6			
deaths causally related to treatment / all	0 / 0			
Disease Progression				
subjects affected / exposed	20 / 981 (2.04%)			
occurrences causally related to treatment / all	0 / 22			
deaths causally related to treatment / all	0 / 15			
Fatigue				
subjects affected / exposed	8 / 981 (0.82%)			
occurrences causally related to treatment / all	15 / 15			
deaths causally related to treatment / all	0 / 0			
General Physical Health Deterioration				
subjects affected / exposed	9 / 981 (0.92%)			
occurrences causally related to treatment / all	4 / 9			
deaths causally related to treatment / all	1 / 3			
Influenza Like Illness				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Malaise				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Multi-Organ Failure				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Oedema Peripheral				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pain				

subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	16 / 981 (1.63%)		
occurrences causally related to treatment / all	5 / 16		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Drug Hypersensitivity			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypersensitivity			
subjects affected / exposed	3 / 981 (0.31%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Pelvic Pain			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Scrotal Ulcer			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Acute Respiratory Failure			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	1 / 2		
Dyspnoea			

subjects affected / exposed	7 / 981 (0.71%)			
occurrences causally related to treatment / all	0 / 9			
deaths causally related to treatment / all	0 / 1			
Epistaxis				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Pleural Effusion				
subjects affected / exposed	2 / 981 (0.20%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Pneumonitis				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumothorax				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pulmonary Artery Thrombosis				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pulmonary Embolism				
subjects affected / exposed	7 / 981 (0.71%)			
occurrences causally related to treatment / all	0 / 7			
deaths causally related to treatment / all	0 / 1			
Pulmonary Microemboli				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pulmonary Oedema				

subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Respiratory Failure			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 1		
Psychiatric disorders			
Confusional State			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Haemoglobin Decreased			
subjects affected / exposed	6 / 981 (0.61%)		
occurrences causally related to treatment / all	6 / 8		
deaths causally related to treatment / all	0 / 0		
Neutrophil Count Decreased			
subjects affected / exposed	3 / 981 (0.31%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Platelet Count Decreased			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
White Blood Cell Count Decreased			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Cystitis Radiation			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Fall				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Femur Fracture				
subjects affected / exposed	3 / 981 (0.31%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Humerus Fracture				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infusion Related Reaction				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Ligament Injury				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Ligament Rupture				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Spinal Compression Fracture				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Spinal Cord Injury Cauda Equina				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Traumatic Fracture				



subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Angina Pectoris			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atrial Fibrillation			
subjects affected / exposed	4 / 981 (0.41%)		
occurrences causally related to treatment / all	2 / 4		
deaths causally related to treatment / all	0 / 0		
Atrial Tachycardia			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Cardiac Disorder			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardiac Failure			
subjects affected / exposed	3 / 981 (0.31%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Cardiac Failure Congestive			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Cardio-Respiratory Arrest			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Cardiogenic Shock			

subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardiopulmonary Failure			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Left Ventricular Dysfunction			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myocardial Infarction			
subjects affected / exposed	3 / 981 (0.31%)		
occurrences causally related to treatment / all	1 / 3		
deaths causally related to treatment / all	0 / 1		
Supraventricular Tachycardia			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Aphasia			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral Haemorrhage			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral Ischaemia			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular Accident			

subjects affected / exposed	2 / 981 (0.20%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 1			
Dizziness				
subjects affected / exposed	2 / 981 (0.20%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
Hepatic Encephalopathy				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Loss Of Consciousness				
subjects affected / exposed	2 / 981 (0.20%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 1			
Nerve Root Compression				
subjects affected / exposed	3 / 981 (0.31%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 0			
Paraesthesia				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Paraplegia				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Paresis				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Presyncope				

subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Spinal Cord Compression			
subjects affected / exposed	11 / 981 (1.12%)		
occurrences causally related to treatment / all	0 / 17		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	4 / 981 (0.41%)		
occurrences causally related to treatment / all	4 / 4		
deaths causally related to treatment / all	1 / 1		
Anaemia			
subjects affected / exposed	12 / 981 (1.22%)		
occurrences causally related to treatment / all	19 / 22		
deaths causally related to treatment / all	0 / 0		
Disseminated Intravascular Coagulation			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Febrile Neutropenia			
subjects affected / exposed	52 / 981 (5.30%)		
occurrences causally related to treatment / all	58 / 58		
deaths causally related to treatment / all	2 / 2		
Granulocytopenia			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Haemorrhagic Anaemia			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Leukopenia			

subjects affected / exposed	7 / 981 (0.71%)		
occurrences causally related to treatment / all	7 / 7		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	24 / 981 (2.45%)		
occurrences causally related to treatment / all	24 / 25		
deaths causally related to treatment / all	0 / 0		
Pancytopenia			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Thrombocytopenia			
subjects affected / exposed	4 / 981 (0.41%)		
occurrences causally related to treatment / all	3 / 4		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal Discomfort			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abdominal Distension			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abdominal Pain			
subjects affected / exposed	6 / 981 (0.61%)		
occurrences causally related to treatment / all	3 / 7		
deaths causally related to treatment / all	0 / 0		
Abdominal Pain Lower			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Colitis			

subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Constipation				
subjects affected / exposed	5 / 981 (0.51%)			
occurrences causally related to treatment / all	3 / 7			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				
subjects affected / exposed	25 / 981 (2.55%)			
occurrences causally related to treatment / all	26 / 28			
deaths causally related to treatment / all	0 / 0			
Duodenal Perforation				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Duodenal Ulcer				
subjects affected / exposed	3 / 981 (0.31%)			
occurrences causally related to treatment / all	3 / 3			
deaths causally related to treatment / all	0 / 0			
Dyspepsia				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Enterovesical Fistula				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Faecal Incontinence				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastric Ulcer				

subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastric Ulcer Haemorrhage			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Gastrointestinal Haemorrhage			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	1 / 1		
Intestinal Obstruction			
subjects affected / exposed	3 / 981 (0.31%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Large Intestine Perforation			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Nausea			
subjects affected / exposed	9 / 981 (0.92%)		
occurrences causally related to treatment / all	9 / 10		
deaths causally related to treatment / all	0 / 0		
Neutropenic Colitis			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	1 / 1		
Pancreatitis Acute			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Proctitis			

subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Rectal Haemorrhage			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Retching			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Small Intestinal Obstruction			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper Gastrointestinal Haemorrhage			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	12 / 981 (1.22%)		
occurrences causally related to treatment / all	10 / 14		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatic Failure			
subjects affected / exposed	4 / 981 (0.41%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	1 / 3		
Hepatic Function Abnormal			



subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatotoxicity			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Anuria			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Bladder Neck Obstruction			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Bladder Perforation			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cystitis Haemorrhagic			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	33 / 981 (3.36%)		
occurrences causally related to treatment / all	5 / 48		
deaths causally related to treatment / all	0 / 1		
Haemorrhage Urinary Tract			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hydronephrosis			

subjects affected / exposed	5 / 981 (0.51%)		
occurrences causally related to treatment / all	0 / 13		
deaths causally related to treatment / all	0 / 1		
Oliguria			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pollakiuria			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal Failure			
subjects affected / exposed	4 / 981 (0.41%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	1 / 3		
Renal Failure Acute			
subjects affected / exposed	12 / 981 (1.22%)		
occurrences causally related to treatment / all	5 / 12		
deaths causally related to treatment / all	2 / 3		
Renal Impairment			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal Pain			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Renal Tubular Necrosis			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary Retention			

subjects affected / exposed	10 / 981 (1.02%)		
occurrences causally related to treatment / all	0 / 14		
deaths causally related to treatment / all	0 / 0		
Urinary Tract Obstruction			
subjects affected / exposed	4 / 981 (0.41%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Urogenital Haemorrhage			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 981 (0.31%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Back Pain			
subjects affected / exposed	13 / 981 (1.33%)		
occurrences causally related to treatment / all	1 / 17		
deaths causally related to treatment / all	0 / 0		
Bone Pain			
subjects affected / exposed	7 / 981 (0.71%)		
occurrences causally related to treatment / all	0 / 10		
deaths causally related to treatment / all	0 / 0		
Flank Pain			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Muscular Weakness			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal Pain			

subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Osteonecrosis Of Jaw			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pain In Extremity			
subjects affected / exposed	4 / 981 (0.41%)		
occurrences causally related to treatment / all	0 / 11		
deaths causally related to treatment / all	0 / 1		
Pain In Jaw			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pathological Fracture			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Spinal Column Stenosis			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Abdominal Sepsis			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Abscess Limb			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Bacterial Sepsis			

subjects affected / exposed	2 / 981 (0.20%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Bronchopneumonia				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Campylobacter Infection				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Candidiasis				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	3 / 981 (0.31%)			
occurrences causally related to treatment / all	1 / 4			
deaths causally related to treatment / all	0 / 0			
Clostridial Infection				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Clostridium Difficile Colitis				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Cystitis				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Device Related Infection				

subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Enterococcal Bacteraemia				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Erysipelas				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haemophilus Infection				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Herpes Zoster				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infection				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	2 / 2			
deaths causally related to treatment / all	0 / 0			
Infectious Peritonitis				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Lobar Pneumonia				

subjects affected / exposed	2 / 981 (0.20%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
Lower Respiratory Tract Infection				
subjects affected / exposed	8 / 981 (0.82%)			
occurrences causally related to treatment / all	3 / 11			
deaths causally related to treatment / all	0 / 0			
Lung Infection				
subjects affected / exposed	3 / 981 (0.31%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 1			
Necrotising Fasciitis				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Neutropenic Infection				
subjects affected / exposed	8 / 981 (0.82%)			
occurrences causally related to treatment / all	10 / 10			
deaths causally related to treatment / all	2 / 2			
Neutropenic Sepsis				
subjects affected / exposed	20 / 981 (2.04%)			
occurrences causally related to treatment / all	20 / 20			
deaths causally related to treatment / all	1 / 1			
Otitis Media				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pelvic Abscess				
subjects affected / exposed	1 / 981 (0.10%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Peritonitis				

subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Pneumonia			
subjects affected / exposed	16 / 981 (1.63%)		
occurrences causally related to treatment / all	14 / 21		
deaths causally related to treatment / all	3 / 3		
Pneumonia Viral			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pseudomembranous Colitis			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Pseudomonas Infection			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory Tract Infection			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	14 / 981 (1.43%)		
occurrences causally related to treatment / all	10 / 16		
deaths causally related to treatment / all	1 / 2		
Septic Shock			



subjects affected / exposed	6 / 981 (0.61%)		
occurrences causally related to treatment / all	5 / 6		
deaths causally related to treatment / all	2 / 2		
Urethritis			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	2 / 2		
deaths causally related to treatment / all	0 / 0		
Urinary Tract Infection			
subjects affected / exposed	20 / 981 (2.04%)		
occurrences causally related to treatment / all	5 / 28		
deaths causally related to treatment / all	2 / 3		
Urosepsis			
subjects affected / exposed	6 / 981 (0.61%)		
occurrences causally related to treatment / all	2 / 7		
deaths causally related to treatment / all	0 / 2		
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Decreased Appetite			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	8 / 981 (0.82%)		
occurrences causally related to treatment / all	6 / 8		
deaths causally related to treatment / all	0 / 0		
Diabetic Ketoacidosis			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	1 / 1		
Gout			

subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Hyperkalaemia			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hypocalcaemia			
subjects affected / exposed	2 / 981 (0.20%)		
occurrences causally related to treatment / all	2 / 3		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemia			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			
subjects affected / exposed	1 / 981 (0.10%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Cabazitaxel		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	851 / 981 (86.75%)		
Nervous system disorders			
Dysgeusia			
subjects affected / exposed	100 / 981 (10.19%)		
occurrences (all)	265		
Neuropathy Peripheral			

subjects affected / exposed occurrences (all)	64 / 981 (6.52%) 117		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	284 / 981 (28.95%)		
occurrences (all)	864		
Leukopenia			
subjects affected / exposed	90 / 981 (9.17%)		
occurrences (all)	142		
Neutropenia			
subjects affected / exposed	216 / 981 (22.02%)		
occurrences (all)	368		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	224 / 981 (22.83%)		
occurrences (all)	634		
Fatigue			
subjects affected / exposed	299 / 981 (30.48%)		
occurrences (all)	1018		
Oedema Peripheral			
subjects affected / exposed	64 / 981 (6.52%)		
occurrences (all)	130		
Pyrexia			
subjects affected / exposed	75 / 981 (7.65%)		
occurrences (all)	87		
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	57 / 981 (5.81%)		
occurrences (all)	88		
Constipation			
subjects affected / exposed	175 / 981 (17.84%)		
occurrences (all)	364		
Diarrhoea			
subjects affected / exposed	393 / 981 (40.06%)		
occurrences (all)	884		
Nausea			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Stomatitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Vomiting</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>273 / 981 (27.83%)</p> <p>622</p> <p>67 / 981 (6.83%)</p> <p>108</p> <p>184 / 981 (18.76%)</p> <p>268</p>		
<p>Respiratory, thoracic and mediastinal disorders</p> <p>Cough</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Dyspnoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>59 / 981 (6.01%)</p> <p>97</p> <p>56 / 981 (5.71%)</p> <p>106</p>		
<p>Renal and urinary disorders</p> <p>Haematuria</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>129 / 981 (13.15%)</p> <p>248</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Back Pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Bone Pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Pain In Extremity</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>78 / 981 (7.95%)</p> <p>155</p> <p>121 / 981 (12.33%)</p> <p>289</p> <p>81 / 981 (8.26%)</p> <p>167</p> <p>64 / 981 (6.52%)</p> <p>115</p>		
<p>Infections and infestations</p> <p>Urinary Tract Infection</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>70 / 981 (7.14%)</p> <p>113</p>		

Metabolism and nutrition disorders Decreased Appetite subjects affected / exposed occurrences (all)	192 / 981 (19.57%) 464		
--	---------------------------	--	--

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 September 2010	It included the following changes: <ul style="list-style-type: none"><li>- Title and objectives were modified in order to emphasize the objective safety.</li><li>- Recruitment objectives (number of sites and subjects) were increased.</li><li>- The treatment duration was harmonized throughout the protocol's sections.</li><li>- The definition of Adverse Events collection period was harmonized.</li></ul>
09 February 2011	It included the following changes: <ul style="list-style-type: none"><li>- Exclusion criteria was clarified.</li><li>- The dosing regimen was clarified.</li><li>- The use of concomitant treatment was clarified.</li><li>- The data collection was clarified.</li></ul>
27 June 2011	It included the following changes: <ul style="list-style-type: none"><li>- Duration of treatment was prolonged if clinical benefit and no toxicity.</li><li>- Chemotherapy delay/reduction was clarified.</li><li>- Neutropenia management: data collection addition of the use of Granulocyte Colony-Stimulating Factor (G-CSF).</li><li>- SAEs reporting was corrected.</li><li>- Hematological toxicities reporting was clarified.</li><li>- The Interim analysis section was updated.</li></ul>
22 December 2011	It included the following changes: <ul style="list-style-type: none"><li>- Exclusion criteria was clarified.</li><li>- The information on preparation and administration of cabazitaxel, and storage of the premix and infusion solution was updated.</li></ul>

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported